Canaccord Genuity initiates coverage of Kailera Therapeutics with buy rating, $44 target
KLRA•Canaccord Genuity initiated coverage of Kailera Therapeutics with a buy rating and a $44 price target.
Related News
AMEX halts LITC; last price 7.609300
LITC•
Surgery Partners and Healthspan Partners announce amended merger agreement after unsolicited proposal
SGRY•
Enbridge files for subordinated notes due 2057 in two series, size not disclosed
ENB•
Alliance Entertainment leads ArtPics funding round with strategic investment
AENT•
Humana commences cash offers to purchase certain outstanding debt securities
HUM•